Eloxx Pharmaceuticals, Inc. has reported its financial results for the third quarter of 2026, marking significant progress in its clinical development efforts. The company has dosed its first two patients in a global Phase 2b study of exaluren for treating nonsense mutation Alport syndrome. Additionally, Eloxx received FDA clearance for a Phase 2 study targeting autosomal dominant polycystic kidney disease (ADPKD). These developments are crucial as they indicate the company's commitment to advancing treatments for rare kidney diseases.
On November 16, 2026, Eloxx Pharmaceuticals, known for its focus on rare kidney diseases, filed an 8-K with the SEC, detailing its financial results for the quarter ended September 30, 2026. The company operates under the SIC code 2836, which pertains to biological products (no diagnostic substances). Eloxx trades on the Nasdaq under the ticker symbol ELOX.
The filing reveals that Eloxx's recent achievements include the initiation of the Phase 2b EXACT study, which aims to enroll 24 patients with Alport syndrome caused by nonsense mutations. The primary efficacy endpoint is the change in podocyte foot process effacement, assessed through kidney biopsies. Topline data from the 16-week placebo-controlled portion of the trial is expected in mid-2027.
Moreover, Eloxx has finalized the protocol for the Phase 2 EXPRESS study in ADPKD and has received IND clearance, allowing it to begin U.S. clinical sites. The company anticipates dosing its first patient in this study in the third quarter of 2027. Eloxx's cash and cash equivalents stood at $56.3 million as of September 30, 2026, providing a solid financial foundation for its ongoing research and development efforts.
The advancements reported in Eloxx's filing may have significant implications for various stakeholders, including patients suffering from rare kidney diseases, healthcare providers, and investors. The company's progress in clinical trials could pave the way for new treatment options, potentially improving patient outcomes and addressing unmet medical needs.
As for what's next, Eloxx is expected to continue its clinical trials and may provide further updates in future filings. The company’s ongoing efforts to expand its leadership team and enhance its clinical programs reflect its strategic focus on becoming a leader in the biopharmaceutical sector.
Read Next
Cadiz Inc. reports Q3 results, shows $7.07 million loss
Ascentage Pharma's Drugs Included in China's Reimbursement List
IGI CEO to Present at Southwest IDEAS Investor Conference
Unicycive Therapeutics announces third-quarter results
FF EAI Robotics Ecosystem reports Q3 results amid challenges
Wetouch Technology Inc. Reports Q3 2026 Financial Results






